Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Conradi

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|December 1, 1978
The predictable relationship between plasma levels and dose during chronic propranolol therapyT Walle, E C Conradi, U K Walle, et al.
Clinical Pharmacology and Therapeutics|August 1, 1979
Presystemic and systemic glucuronidation of propranololT Walle, T C Fagan, E C Conradi, et al.
Clinical Pharmacology and Therapeutics|November 1, 1979
Naphthoxylactic acid after single and long-term doses of propranololT Walle, E C Conradi, U K Walle, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 1, 1990
Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in manT Walle, U K Walle, T D Cowart, et al.
British Journal of Clinical Pharmacology|January 1, 1994
The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomersU K Walle, T C Fagan, M J Topmiller, et al.
IET Systems Biology|April 10, 2008
Multistability of signal transduction motifsJ Saez-Rodriguez, A Hammerle-Fickinger, O Dalal, et al.
British Journal of Clinical Pharmacology|April 1, 1982
Early kinetics of intravenous propranololT C Fagan, T Walle, U K Walle, et al.
Clinical Pharmacology and Therapeutics|October 1, 1986
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesisL S Olanoff, T Walle, T D Cowart, et al.
Clinical Pharmacology and Therapeutics|December 1, 1981
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolitesT Walle, T C Fagan, U K Walle, et al.
World Journal of Surgical Oncology|April 15, 2010
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?Thilo Sprenger, Hilka Rothe, Klaus Jung, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|December 1, 1978
The predictable relationship between plasma levels and dose during chronic propranolol therapyT Walle, E C Conradi, U K Walle, et al.
Clinical Pharmacology and Therapeutics|August 1, 1979
Presystemic and systemic glucuronidation of propranololT Walle, T C Fagan, E C Conradi, et al.
Clinical Pharmacology and Therapeutics|November 1, 1979
Naphthoxylactic acid after single and long-term doses of propranololT Walle, E C Conradi, U K Walle, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 1, 1990
Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in manT Walle, U K Walle, T D Cowart, et al.
British Journal of Clinical Pharmacology|January 1, 1994
The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomersU K Walle, T C Fagan, M J Topmiller, et al.
IET Systems Biology|April 10, 2008
Multistability of signal transduction motifsJ Saez-Rodriguez, A Hammerle-Fickinger, O Dalal, et al.
British Journal of Clinical Pharmacology|April 1, 1982
Early kinetics of intravenous propranololT C Fagan, T Walle, U K Walle, et al.
Clinical Pharmacology and Therapeutics|October 1, 1986
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesisL S Olanoff, T Walle, T D Cowart, et al.
Clinical Pharmacology and Therapeutics|December 1, 1981
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolitesT Walle, T C Fagan, U K Walle, et al.
World Journal of Surgical Oncology|April 15, 2010
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?Thilo Sprenger, Hilka Rothe, Klaus Jung, et al.
Pageof 4